These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Pharmacogenomics of osteoporosis: opportunities and challenges. Nguyen TV; Eisman JA J Musculoskelet Neuronal Interact; 2006; 6(1):62-72. PubMed ID: 16675890 [TBL] [Abstract][Full Text] [Related]
5. Pharmacogenomics: historical perspective and current status. Charlab R; Zhang L Methods Mol Biol; 2013; 1015():3-22. PubMed ID: 23824846 [TBL] [Abstract][Full Text] [Related]
6. HLA: a pharmacogenomics success story. Becquemont L Pharmacogenomics; 2010 Mar; 11(3):277-81. PubMed ID: 20235781 [No Abstract] [Full Text] [Related]
7. Pharmacogenomics of adverse drug reactions: practical applications and perspectives. Becquemont L Pharmacogenomics; 2009 Jun; 10(6):961-9. PubMed ID: 19530963 [TBL] [Abstract][Full Text] [Related]
8. [Genetics and pharmacogenetics of osteoporosis]. Zofková I; Omelka R Vnitr Lek; 2014; 60(7-8):575-81. PubMed ID: 25130632 [TBL] [Abstract][Full Text] [Related]
9. The future of pharmacogenetics for osteoporosis. Marini F; Brandi ML Pharmacogenomics; 2013 Apr; 14(6):641-53. PubMed ID: 23570468 [TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics of osteoporosis and the prospect of individualized prognosis and individualized therapy. Nguyen TV; Center JR; Eisman JA Curr Opin Endocrinol Diabetes Obes; 2008 Dec; 15(6):481-8. PubMed ID: 18971675 [TBL] [Abstract][Full Text] [Related]
12. [Perspectives in the treatment of osteoporosis]. Passeri M Recenti Prog Med; 1999 Sep; 90(9):451-4. PubMed ID: 10544665 [No Abstract] [Full Text] [Related]
13. Pharmacogenomics--10 years of progress: a cardiovascular perspective. Winkelmann BR; Herrington D Pharmacogenomics; 2010 May; 11(5):613-6. PubMed ID: 20415546 [TBL] [Abstract][Full Text] [Related]
14. An overview of osteoporosis: from genetics to clinics. Brandi ML Aging Clin Exp Res; 2011 Apr; 23(2 Suppl):3-5. PubMed ID: 21970903 [TBL] [Abstract][Full Text] [Related]
15. Complications & side effects. Benefits of bone drugs appear to outweigh risks. TreatmentUpdate; 2007; 19(4):7-8. PubMed ID: 17969260 [No Abstract] [Full Text] [Related]
16. [Use of bisphosphonates in the treatment of systemic osteoporosis]. Rodionova SS; Zatsepin ST; Shvets VN; Matkovskaia TA Ortop Travmatol Protez; 1989 Mar; (3):51-6. PubMed ID: 2740116 [No Abstract] [Full Text] [Related]
17. Pharmacogenetics of osteoporosis: towards novel theranostics for personalized medicine? Rojo Venegas K; Aguilera Gómez M; Cañada Garre M; Sánchez AG; Contreras-Ortega C; Calleja Hernández MA OMICS; 2012 Dec; 16(12):638-51. PubMed ID: 23215803 [TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics of osteoporosis: what is the evidence? Marini F; Brandi ML Curr Osteoporos Rep; 2012 Sep; 10(3):221-7. PubMed ID: 22760517 [TBL] [Abstract][Full Text] [Related]
19. Insights into the genetics of osteoporosis from recent genome-wide association studies. Zheng HF; Spector TD; Richards JB Expert Rev Mol Med; 2011 Aug; 13():e28. PubMed ID: 21867596 [TBL] [Abstract][Full Text] [Related]
20. Current controversies in bisphosphonate therapy. Kamath AF Orthopedics; 2009 Jul; 32(7):473. PubMed ID: 19634857 [No Abstract] [Full Text] [Related] [Next] [New Search]